Skip to content

8-KAccepted Nov 5, 8:08 AM ET

InMed Pharmaceuticals: reports approval of name change and share consolidation

MTRIInMed Pharmaceuticals Inc.

Accepted (ET)

8:08 AM

Nov 5, 2026

Filed

Nov 5, 2026

Documents

15

Size

299.9 KB

Summary

InMed Pharmaceuticals: reports approval of name change and share consolidation

Updated

What happened On Nov 4, 2026, InMed Pharmaceuticals Inc. (MTRI) reported results of its 2026 annual general and special meeting and reported approval of a corporate name change and completion of a share consolidation.

Key details

  • Item 7.01: regulation FD disclosure reporting the meeting results, approval of a corporate name change and completion of a share consolidation.
  • Item 9.01: exhibits were furnished (the filing states the exhibits are furnished and not filed).
  • The filing references a news release dated Nov 4, 2026.

Why it may matter The filing reports Item 7.01, regulation FD disclosure, which covers disclosure of the meeting results and corporate actions announced at that meeting (name change approval and share consolidation completion). Item 9.01 indicates certain exhibits were furnished with the filing. The filing does not explain why the company acted or why any insider traded.

AI-written summary · check the filing